Autoantigens Plus Interleukin-10 Suppress Diabetes Autoimmunity

被引:17
|
作者
Denes, Bela [1 ,2 ]
Fodor, Istvan [1 ]
Langridge, William H. R. [1 ]
机构
[1] Loma Linda Univ, Ctr Hlth Dispar & Mol Med, Dept Biochem & Microbiol, Loma Linda, CA 92350 USA
[2] Cent Vet Inst, Dept Immunol, Budapest, Hungary
基金
美国国家卫生研究院;
关键词
TOXIN B-SUBUNIT; GLUTAMIC-ACID DECARBOXYLASE; ANTIGEN-PRESENTING CELLS; REGULATORY T-CELLS; CHOLERA-TOXIN; NOD MICE; VACCINIA VIRUS; GENE-TRANSFER; MUCOSAL IMMUNITY; TRANSGENIC EXPRESSION;
D O I
10.1089/dia.2009.0116
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recombinant vaccinia virus (rVV) strains expressing the immunomodulatory cholera toxin B subunit (CTB) fused to the autoantigen glutamic acid decarboxylase (GAD) or the immunosuppressive cytokine interleukin-10 (IL-10) were independently able to generate only low levels of immune suppression of type 1 diabetes mellitus (T1DM). Here we suggest that a vaccinia virus (VV)-mediated combination of CTB::GAD fusion and IL-10 proteins promises a effective and durable immunotherapeutic strategy for T1DM. Methods: To explore this hypothesis, a CTB::GAD fusion gene was co-delivered with a gene encoding IL-10 by rVV infection (rVV-CTB::GAD+rVV-IL10) into 5-7-week-old non-obese diabetic (NOD) mice. The mice were assessed for vaccine protection against development of hyperglycemia from 12 to 64 weeks of age by assessment of pancreatic inflammation (insulitis) and splenocyte-secreted interferon-gamma and IL-10 cytokine levels. Results: By 36 weeks of age, from 54% to 80% of the mice in the negative control animal groups (either mock-infected or inoculated with unrelated plasmid or VV) had developed hyperglycemia. Similarly, no statistically significant improvement in protection against diabetes onset was achieved by inoculation with VV expressing CTB::GAD or IL-10 independently. Surprisingly, only 20% of mice co-inoculated with rVV-CTB::GAD+rVV-IL10 developed hyperglycemia by 28 weeks of age. Other treatment groups developed hyperglycemia by 32-36 weeks. After 36 weeks, diabetes incidence no longer increased in any groups until the end of experiment at 64 weeks of age. Histological analysis of pancreatic tissues of hyperglycemic mice revealed high levels of intra-islet insulitis. Analysis of insulitis at termination of the experiment showed that euglycemic mice co-inoculated with VV expressing CTB::GAD and IL-10 had more effectively reduced inflammation in comparison with the other groups. Conclusions: A combinatorial vaccination strategy based on VV co-delivery of genes encoding the immuno-enhanced autoantigen CTB::GAD and the anti-inflammatory cytokine IL-10 can maintain effective and durable euglycemia and immunological homeostasis in NOD mice with prediabetes.
引用
收藏
页码:649 / 661
页数:13
相关论文
共 50 条
  • [41] The levels of interleukin-2 and interleukin-10 in patients with type 2 diabetes and colon cancer
    Bosek, Irina
    Kuczerowski, Roman
    Milek, Tomasz
    Rabijewski, Michal
    Kaleta, Beata
    Kniotek, Monika
    Ciostek, Piotr
    Piatkiewicz, Pawel
    CLINICAL DIABETOLOGY, 2018, 7 (02): : 114 - 121
  • [42] Regulation of Interleukin-10 Expression
    Rutz, Sascha
    Ouyang, Wenjun
    REGULATION OF CYTOKINE GENE EXPRESSION IN IMMUNITY AND DISEASES, 2016, 941 : 89 - 116
  • [43] Interleukin-10 stiffens the heart
    Cihakova, Daniela
    JOURNAL OF EXPERIMENTAL MEDICINE, 2018, 215 (02): : 379 - 381
  • [44] INTERLEUKIN-10 AND RHEUMATOID SYNOVITIS
    MIOSSEC, P
    CHOMARAT, P
    RISSOAN, MC
    BANCHEREAU, J
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 146 - 146
  • [45] The role of interleukin-10 in asthma
    Yang, Z.
    Li, N.
    Koelle, J.
    Rieker, R. J.
    Finotto, S.
    ALLERGY, 2020, 75 : 369 - 369
  • [46] MACROPHAGE DEACTIVATION BY INTERLEUKIN-10
    BOGDAN, C
    VODOVOTZ, Y
    NATHAN, C
    JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (06): : 1549 - 1555
  • [47] BIOLOGICAL PROPERTIES OF INTERLEUKIN-10
    HOWARD, M
    OGARRA, A
    ISHIDA, H
    MALEFYT, RD
    DEVRIES, J
    JOURNAL OF CLINICAL IMMUNOLOGY, 1992, 12 (04) : 239 - 247
  • [48] BIOLOGICAL PROPERTIES OF INTERLEUKIN-10
    HOWARD, M
    OGARRA, A
    IMMUNOLOGY TODAY, 1992, 13 (06): : 198 - 200
  • [49] Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse
    Kamanaka, Masahito
    Kim, Sean T.
    Wan, Yisong Y.
    Sutterwala, Fayyaz S.
    Lara-Tejero, Maria
    Galan, Jorge E.
    Harhaj, Ed
    Flavell, Richard A.
    IMMUNITY, 2006, 25 (06) : 941 - 952
  • [50] Investigation of Interleukin-10 Promoter Polymorphisms and Interleukin-10 Levels in Children with Irritable Bowel Syndrome
    Hua, Man-Chin
    Chao, Hsun-Chin
    Yao, Tsung-Chieh
    Lai, Ming-Wei
    Huang, Jing-Long
    GUT AND LIVER, 2013, 7 (04) : 430 - 436